Just coming back from an NCI Division of Cancer Biology Cancer Moonshot meeting. Let me tell you that the future is bright for cancer treatment. What an inspiring group of researchers! #PIDDN2022
#PIDDN2022: Mackall Lab Stanford University is moderating a #PIDDN poster preview (a.k.a. lightning talk) session at #Research4ChildhoodCancer.
At #PIDDN2022, Stephan Grupp MD PhD Children's Hospital is presenting determinants and markers of exceptional response and T cell dysfunction in #CARTcell therapy. #Research4ChildhoodCancer
#PIDDN2022: Dr. Tim Cripe, M.D. Ph.D Nationwide Children's Hospital is discussing the targeting of circulating tumor cells (#CTCs) in #ChildhoodCancers. #Research4ChildhoodCancer
Dr. Paul Sondel UW–Madison is moderating Session 4 of #PIDDN2022, which is exploring the biology of #ChildhoodCancers and preclinical development of immunotherapeutic strategies to treat pediatric tumors. #Research4ChildhoodCancer
At #PIDDN2022, Dr. Joshua Hill Fred Hutchinson Cancer Center is presenting his studies characterizing antibody levels and vaccine responses after #CART therapy for B cell malignancies. #Research4ChildhoodCancer
Dr. Gregg Morin BC Cancer, Kara Davis Stanford Medicine, Dr. Sujith Joseph BCMHouston, Quinlen Marshall Children's Hospital, & Dr. Amy Erbe-Gurel UW–Madison are sharing their work identifying treatment targets and developing #immunotherapy approaches for #ChildhoodCancers at #PIDDN2022.
Session 3 of #PIDDN2022, moderated by Dr Ruoning Wang Nationwide Children's Hospital, is exploring mechanisms of oncogenesis and immune evasion in #ChildhoodCancers that can be targeted by rationally designed #immunotherapies. #Research4ChildhoodCancer
Dr. Stephen Schoenberger La Jolla Institute is giving a keynote talk on the functional identification and therapeutic targeting of cancer #neoantigens at #PIDDN2022. lji.org/labs/schoenber… #Research4ChildhoodCancer.
Nirali Shah NCI CCR Pediatric Oncology Branch sharing valuable clinical pearls for managing CART associated toxicity at the annual meeting of the Pediatric Immunotherapy Discovery & Development Network #PIDDN2022
Dr. Nirali Shah NCI CCR Pediatric Oncology Branch is sharing insights about toxicities of CD22 #CARTcell therapy at #PIDDN2022. Read more in Blood Journal: ncbi.nlm.nih.gov/pmc/articles/P… #Research4ChildhoodCancer
At #PIDDN2022, Sophie Paczesny Medical University of South Carolina (MUSC) is giving an update on the role of ST2/IL33 in #ChildhoodCancer and describing a new molecule expressed on cancer cells that influences the #tumormicroenvironment. #Research4ChildhoodCancer
#PIDDN2022: Andrei Thomas-T. Children's Hospital & Mathieu Quesnel-Vallieres Penn Genetics are presenting their studies on novel exon junctions in #PediatricCancers. #Research4ChildhoodCancer
#PIDDN2022: Dr. Verena Staedtke Johns Hopkins Medicine is sharing the role of the catecholaminergic pathway in #CARTcell therapy. #Research4ChildhoodCancer
Dr. Sarah Tasian Children's Hospital is discussing combinatorial targeting of FLT3 in childhood #leukemias at #PIDDN2022. #Research4ChildhoodCancer
Dr. James Olsen Seattle Children's is moderating Session 2 of #PIDDN2022, which is focusing on fundamental mechanisms in #PediatricCancers that inform the development of #immunotherapies. #Research4ChildhoodCancer
Dr. Wen Luo New York Medical College, as well as Marcelo Pereira, Ilse Hernandez Aguirre, Jack Hedberg 🧬, Dr. Katherine Miller & Dr. JN Rashida Gnanaprakasam Nationwide Children's Hospital are sharing experimental strategies to inform the development of #immunotherapies for #ChildhoodCancers at #PIDDN2022.
Session 1 of #PIDDN2022, moderated by Dr. Sarah Tasian Children's Hospital, is examining preclinical approaches that harness immunity to target #ChildhoodCancers. #Research4ChildhoodCancer
Dr. Rosandra Kaplan giving her keynote talk at the The Pediatric Immunotherapy Discovery and Development Network (#PIDDN2022) Meeting on her work using engineered immune cells to reverse the immune suppressive metastatic niche microenvironment! Learn more: go.cancer.gov/8DGrG6j
